DrugPatentWatch Database Preview
Details for Patent: 7,772,209
» See Plans and Pricing
Which drugs does patent 7,772,209 protect, and when does it expire?
Patent 7,772,209 protects PEMFEXY and ALIMTA and is included in two NDAs.
Protection for ALIMTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has eighteen patent family members in eleven countries.
Summary for Patent: 7,772,209
| Title: | Antifolate combination therapies |
| Abstract: | A method of administering an antifolate to a mammal in need thereof, comprising administering an effective amount of said antifolate in combination with a methylmalonic acid lowering agent. |
| Inventor(s): | Niyikiza; Clet (Indianapolis, IN) |
| Assignee: | Eli Lilly and Company (Indianapolis, IN) |
| Application Number: | 11/776,329 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,772,209 |
|
Patent Claim Types: see list of patent claims | Use; Delivery; |
Drugs Protected by US Patent 7,772,209
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eagle Pharms | PEMFEXY | pemetrexed | SOLUTION;INTRAVENOUS | 209472-001 | Feb 8, 2020 | RX | Yes | Yes | Start Trial | Start Trial | USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION IN PATIENTS WITH MESOTHELIOMA | Start Trial | ||||
| Eagle Pharms | PEMFEXY | pemetrexed | SOLUTION;INTRAVENOUS | 209472-001 | Feb 8, 2020 | RX | Yes | Yes | Start Trial | Start Trial | USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION IN PATIENTS WITH NON-SQUAMOUS NON-SMALL CELL LUNG CANCER | Start Trial | ||||
| Lilly | ALIMTA | pemetrexed disodium | POWDER;INTRAVENOUS | 021462-002 | Sep 7, 2007 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||||
| Lilly | ALIMTA | pemetrexed disodium | POWDER;INTRAVENOUS | 021462-001 | Feb 4, 2004 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,772,209
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 359823 | Start Trial | |||
| Australia | 6968801 | Start Trial | |||
| Cyprus | 1107649 | Start Trial | |||
| Germany | 60127970 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
